Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
7 NC counties are under alert, including Johnston County.
Program
Former President Obama headlining night 2 of the DNC. His strong endorsement of VP Harris and his hopes for November
Program
On WRAL at 6: Hidden fees in your childâs school lunch payment ð¨ð¸ 5 On Your Side shows you how to keep more money in your pocket
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Rocket Pharmaceuticals, Inc.
< Previous
1
2
Next >
Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
August 05, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
June 28, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
May 29, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
May 10, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
May 06, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
April 02, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
March 26, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
February 26, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
February 13, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
December 12, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
November 06, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
October 19, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
October 02, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference
September 26, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock
September 13, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
September 12, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease
September 12, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
September 06, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
August 10, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
June 08, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease
May 31, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD)
May 23, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
May 19, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
May 09, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress
May 04, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
April 11, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage
April 04, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference
March 01, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
February 27, 2023
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Tickers
RCKT
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.